

Andrew J Wiemer

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3846120/publications.pdf>

Version: 2024-02-01

59
papers

1,636
citations

218592

26
h-index

315616

38
g-index

63
all docs

63
docs citations

63
times ranked

1755
citing authors

#	ARTICLE	IF	CITATIONS
1	Prodrugs of Phosphonates and Phosphates: Crossing the Membrane Barrier. Topics in Current Chemistry, 2014, 360, 115-160.	4.0	135
2	Contact-Dependent T Cell Activation and T Cell Stopping Require Talin1. Journal of Immunology, 2011, 187, 6256-6267.	0.4	91
3	Synthesis of a Phosphoantigen Prodrug that Potently Activates V β 9V α 2 T-Lymphocytes. Chemistry and Biology, 2014, 21, 945-954.	6.2	86
4	Synthesis and biological activity of isoprenoid bisphosphonates. Bioorganic and Medicinal Chemistry, 2006, 14, 4130-4136.	1.4	69
5	Digeranyl bisphosphonate inhibits geranylgeranyl pyrophosphate synthase. Biochemical and Biophysical Research Communications, 2007, 353, 921-925.	1.0	69
6	Geranylgeranyl Diphosphate Synthase: An Emerging Therapeutic Target. Clinical Pharmacology and Therapeutics, 2011, 90, 804-812.	2.3	64
7	The Intermediate Enzymes of Isoprenoid Metabolism as Anticancer Targets. Anti-Cancer Agents in Medicinal Chemistry, 2009, 9, 526-542.	0.9	60
8	Stepping forward in antibody-drug conjugate development. , 2022, 229, 107917.		60
9	Cyclopropene Cycloadditions with Annulated Furans: Total Synthesis of (+)- and (âˆ-)Frondosin B and (+)-Frondosin A. Journal of the American Chemical Society, 2014, 136, 4309-4315.	6.6	55
10	Pivaloyloxymethyl-modified isoprenoid bisphosphonates display enhanced inhibition of cellular geranylgeranylation. Bioorganic and Medicinal Chemistry, 2008, 16, 3652-3660.	1.4	50
11	Inhibition of Geranylgeranyl Diphosphate Synthase Induces Apoptosis through Multiple Mechanisms and Displays Synergy with Inhibition of Other Isoprenoid Biosynthetic Enzymes. Journal of Pharmacology and Experimental Therapeutics, 2008, 324, 1028-1036.	1.3	45
12	Total synthesis of (R,R,R)- and (S,S,S)-schweinfurthin F: Differences of bioactivity in the enantiomeric series. Bioorganic and Medicinal Chemistry Letters, 2007, 17, 911-915.	1.0	43
13	Mono- and dialkyl isoprenoid bisphosphonates as geranylgeranyl diphosphate synthase inhibitors. Bioorganic and Medicinal Chemistry, 2008, 16, 390-399.	1.4	41
14	Quantitative determination of farnesyl and geranylgeranyl diphosphate levels in mammalian tissue. Analytical Biochemistry, 2008, 378, 138-143.	1.1	41
15	The butyrophilin 3A1 intracellular domain undergoes a conformational change involving the juxtamembrane region. FASEB Journal, 2017, 31, 4697-4706.	0.2	41
16	Metabolic Efficacy of Phosphate Prodrugs and the Remdesivir Paradigm. ACS Pharmacology and Translational Science, 2020, 3, 613-626.	2.5	39
17	Mixed Aryl Phosphonate Prodrugs of a Butyrophilin Ligand. ACS Medicinal Chemistry Letters, 2017, 8, 914-918.	1.3	38
18	Stereoselective Synthesis of the 5â€-Hydroxy-5â€-phosphonate Derivatives of Cytidine and Cytosine Arabinoside. Journal of Organic Chemistry, 2002, 67, 9331-9339.	1.7	36

#	ARTICLE	IF	CITATIONS
19	A Live Imaging Cell Motility Screen Identifies Prostaglandin E2 as a T Cell Stop Signal Antagonist. <i>Journal of Immunology</i> , 2011, 187, 3663-3670.	0.4	35
20	HMBPP Analog Prodrugs Bypass Energy-Dependent Uptake To Promote Efficient BTN3A1-Mediated Malignant Cell Lysis by V β 9V α 2 T Lymphocyte Effectors. <i>Journal of Immunology</i> , 2016, 197, 419-428.	0.4	33
21	Phosphoramidate Prodrugs of a Butyrophilin Ligand Display Plasma Stability and Potent V β 9 V α 2 T Cell Stimulation. <i>Journal of Medicinal Chemistry</i> , 2018, 61, 8658-8669.	2.9	32
22	Synthesis of phosphonate derivatives of uridine, cytidine, and cytosine arabinoside. <i>Bioorganic and Medicinal Chemistry</i> , 2000, 8, 2501-2509.	1.4	31
23	Synthesis and Activity of Fluorescent Isoprenoid Pyrophosphate Analogues. <i>Journal of Organic Chemistry</i> , 2004, 69, 8186-8193.	1.7	28
24	Synthesis of fluorescently tagged isoprenoid bisphosphonates that inhibit protein geranylgeranylation. <i>Bioorganic and Medicinal Chemistry</i> , 2007, 15, 1959-1966.	1.4	28
25	Phosphinophosphonates and Their Tris-pivaloyloxymethyl Prodrugs Reveal a Negatively Cooperative Butyrophilin Activation Mechanism. <i>Journal of Medicinal Chemistry</i> , 2017, 60, 2373-2382.	2.9	28
26	Calpain inhibition impairs TNF- α -mediated neutrophil adhesion, arrest and oxidative burst. <i>Molecular Immunology</i> , 2010, 47, 894-902.	1.0	27
27	Isoprenoid Metabolism as a Therapeutic Target in Gram-Negative Pathogens. <i>Current Topics in Medicinal Chemistry</i> , 2010, 10, 1858-1871.	1.0	27
28	Opportunities and challenges in development of phosphoantigens as V β 9V α 2 T cell agonists. <i>Biochemical Pharmacology</i> , 2014, 89, 301-312.	2.0	26
29	Ligand-induced interactions between butyrophilin 2A1 and 3A1 internal domains in the HMBPP receptor complex. <i>Cell Chemical Biology</i> , 2022, 29, 985-995.e5.	2.5	19
30	The focal adhesion kinase inhibitor PF-562,271 impairs primary CD4+ T cell activation. <i>Biochemical Pharmacology</i> , 2013, 86, 770-781.	2.0	18
31	Molecular mechanisms linking geranylgeranyl diphosphate synthase to cell survival and proliferation. <i>Molecular Membrane Biology</i> , 2016, 33, 1-11.	2.0	18
32	A power law function describes the time- and dose-dependency of V β 9V α 2 T cell activation by phosphoantigens. <i>Biochemical Pharmacology</i> , 2018, 158, 298-304.	2.0	18
33	Novel β -substituted tropolones promote potent and selective caspase-dependent leukemia cell apoptosis. <i>Pharmacological Research</i> , 2016, 113, 438-448.	3.1	17
34	Novel tropolones induce the unfolded protein response pathway and apoptosis in multiple myeloma cells. <i>Oncotarget</i> , 2017, 8, 76085-76098.	0.8	17
35	Toward Broad Spectrum Dihydrofolate Reductase Inhibitors Targeting Trimethoprim Resistant Enzymes Identified in Clinical Isolates of Methicillin Resistant <i>Staphylococcus aureus</i> . <i>ACS Infectious Diseases</i> , 2019, 5, 1896-1906.	1.8	16
36	Synthesis and biological evaluation of santacruzamate A analogues for anti-proliferative and immunomodulatory activity. <i>Bioorganic and Medicinal Chemistry</i> , 2016, 24, 5183-5196.	1.4	15

#	ARTICLE	IF	CITATIONS
37	Geranylgeranyl diphosphate synthase inhibition induces apoptosis that is dependent upon GGPP depletion, ERK phosphorylation and caspase activation. <i>Cell Death and Disease</i> , 2017, 8, e2678-e2678.	2.7	15
38	Structure-Activity Relationships of Butyrophilin 3 Ligands. <i>ChemMedChem</i> , 2020, 15, 1030-1039.	1.6	14
39	New Technologies Bloom Together for Bettering Cancer Drug Conjugates. <i>Pharmacological Reviews</i> , 2022, 74, 680-713.	7.1	14
40	Evaluation of a 7-Methoxycoumarin-3-carboxylic Acid Ester Derivative as a Fluorescent, Cell-Cleavable, Phosphonate Protecting Group. <i>ChemBioChem</i> , 2016, 17, 52-55.	1.3	13
41	Stability and Efficiency of Mixed Aryl Phosphonate Prodrugs. <i>ChemMedChem</i> , 2019, 14, 1597-1603.	1.6	13
42	Synthesis and Bioactivity of the Alanyl Phosphoramidate Stereoisomers Derived from a Butyrophilin Ligand. <i>ACS Medicinal Chemistry Letters</i> , 2019, 10, 1284-1289.	1.3	11
43	Probing the Ligand-Binding Pocket of BTN3A1. <i>Journal of Medicinal Chemistry</i> , 2019, 62, 6814-6823.	2.9	11
44	Regulation of the Notch-ATM-abl axis by geranylgeranyl diphosphate synthase inhibition. <i>Cell Death and Disease</i> , 2019, 10, 733.	2.7	6
45	Tropone-induced effects on the unfolded protein response pathway and apoptosis in multiple myeloma cells are dependent on iron. <i>Leukemia Research</i> , 2019, 77, 17-27.	0.4	6
46	Potent double prodrug forms of synthetic phosphoantigens. <i>Bioorganic and Medicinal Chemistry</i> , 2020, 28, 115666.	1.4	6
47	Synthesis and Metabolism of BTN3A1 Ligands: Studies on Diene Modifications to the Phosphoantigen Scaffold. <i>ACS Medicinal Chemistry Letters</i> , 2022, 13, 164-170.	1.3	5
48	Phosphonate Analogues of Cytosine Arabinoside Monophosphate. <i>Phosphorus, Sulfur and Silicon and the Related Elements</i> , 2002, 177, 1783-1786.	0.8	4
49	Synthesis and Metabolism of BTN3A1 Ligands: Studies on Modifications of the Allylic Alcohol. <i>ACS Medicinal Chemistry Letters</i> , 2021, 12, 136-142.	1.3	4
50	Efficiency of bis-amidate phosphonate prodrugs. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2022, 66, 128724.	1.0	4
51	A luciferase lysis assay reveals in vivo malignant cell sensitization by phosphoantigen prodrugs. <i>Biochemical Pharmacology</i> , 2019, 170, 113668.	2.0	3
52	Generation of Single-Chain Variable Fragment (scFv) Libraries for Use in Phage Display. <i>Current Protocols</i> , 2021, 1, e182.	1.3	3
53	Incorporation of a FRET pair within a phosphonate diester. <i>Bioorganic Chemistry</i> , 2021, 114, 105048.	2.0	3
54	Live Imaging of LFA-1-Dependent T-Cell Motility and Stop Signals. <i>Methods in Molecular Biology</i> , 2011, 757, 191-204.	0.4	2

#	ARTICLE	IF	CITATIONS
55	Generation of effector V β 9V α 2 T α cells and evaluation of their response to phosphoantigen-loaded cells. STAR Protocols, 2022, 3, 101422.	0.5	2
56	Synthesis and Biological Evaluation of a Phosphonate Phosphoantigen Prodrug. Phosphorus, Sulfur and Silicon and the Related Elements, 2015, 190, 751-753.	0.8	1
57	Bisphosphonates Influence Isoprenylation of Small Gtpases in Human Myeloma Cells.. Blood, 2004, 104, 3401-3401.	0.6	0
58	Synergism between Anti-Leukemia Therapeutics and Isoprenoid Pathway Inhibitors in K562 Leukemia Cells.. Blood, 2006, 108, 4815-4815.	0.6	0
59	Effects of Novel Tropolones with Selective HDAC Inhibitor Activity in Myeloma Cells. Blood, 2015, 126, 3247-3247.	0.6	0